Background: Cytochrome P450 2C19 (CYP2C19) is a polymorphically expressed enzyme that shows marked interindividual and interethnic variation. CYP2C19*2 and CYP2C19*3 are the most frequently identified defective alleles in Orientals and Caucasian poor metabolizers (PM). The aim of this study was to investigate the frequencies of CYP2C19*1, CYP2C19*2 and CYP2C19*3 alleles and CYP2C19 genotypes in...

background: cytochrome p450 2c19 (cyp2c19) is a polymorphically expressed enzyme that shows marked interindividual and interethnic variation. cyp2c19*2 and cyp2c19*3 are the most frequently identified defective alleles in orientals and caucasian poor metabolizers (pm). the aim of this study was to investigate the frequencies of cyp2c19*1, cyp2c19*2 and cyp2c19*3 alleles and cyp2c19 genotypes in...

Background: Cytochrome P450 2C19 (CYP2C19) is widely involved in the metabolism of some medications. On the other hand, recent studies have shown the contribution of the CYP2C19 polymorphisms to different malignancies. We aimed to investigate the association between CYP2C19 polymorphism and occurrence of hematological malignancies by comparing the phenotype distribution of this enzyme in patien...

Introduction: Since there has been a dearth of research on the assessment of CYP2C19 polymorphism in the east of Iran (Khorasan provinces), this study aimed to detect, CYP2C19*2 and CYP2C19*3 allele frequencies among patients with coronary artery disease. The participants were selected among those referring to Emam Reza Hospital, Mashhad, Iran. Furthermore, the current research was motivated to...

  Background: Cytochrome P450 2C19 (CYP2C19) is important in metabolism of wide range of drugs. CYP2C19*17 is a novel variant allele which increases gene transcription and therefore results in ultra-rapid metabolizer phenotype (URM). Distribution of this variant allele has not been well studied worldwide. The aim of present study was to investigate allele and genotype frequencies of CYP2C19*17 ...

The interindividual variability of Proton Pump Inhibitor (PPI) therapy results from the phenotype associated with cytochrome P450 2C19 (CYP2C19) gene, namely CYP2C19*17 allele. Our aim was to characterize patients’ genetic undergoing PPI therapy. A sample 33 oral mucosa cells Portuguese pharmacy patients collected, followed by genotyping. allelic frequencies CYP2C19*1 (-806C) and (-806T) were 7...

Abstract Background This research aims to study the association of genetic polymorphism in genes coding for CYP2C9 and CYP2C19 phenytoin-induced dose-related toxicity assess if presence allele CYP2C9*3 plays a role idiosyncratic adverse effects. Current observational case control included 142 patients with drug reactions (ADRs) 100 controls. All these underwent genotyping determine type [CYP2C9...

INTRODUCTION Proton pump inhibitors, which are widely used as acid-inhibitory agents for the treatment of peptic ulcers, are mainly metabolized by 2C19 isoenzyme of cytochrome P450 (CYP2C19). CYP2C19 has genetic polymorphisms, associated with extensive, poor, intermediate or ultra-rapid metabolism of proton pump inhibitors. Genetic polymorphisms of CYP2C19 could be of clinical concern in the tr...